Pharmacist holding prescription Research has found that 78% of drugs associated with new patents were not new drugs coming on the market, but existing drugs. (Photo: Shutterstock)

A new report suggests that "product hopping"—a practice by drug companies to extend their patents on profitable drugs—costs American consumers and the U.S. health care system billions of dollars each year.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.